Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20333471 | 0.92 | HRH3 (0.52) | HRH3SIGMAR1 | |
| SCHEMBL12156673 | 0.90 | HRH3 (0.48) | HRH3SIGMAR1 | |
| SCHEMBL11922753 | 0.88 | HRH3 (0.52) | HRH3 | |
| SCHEMBL25571325 | 0.83 | SIGMAR1 (0.40) | HRH3SIGMAR1MAPT | |
| SCHEMBL16234549 | 0.81 | HRH3 (0.50) | HRH3SIGMAR1MAPT | |
| SCHEMBL16234550 | 0.81 | HRH3 (0.50) | HRH3SIGMAR1MAPT | |
| SCHEMBL5910757 | 0.80 | HRH3 (0.57) | HRH3SIGMAR1MAPT | |
| SCHEMBL12359043 | 0.79 | SIGMAR1 (0.38) | HRH3SIGMAR1 | |
| SCHEMBL13701722 | 0.79 | SIGMAR1 (0.55) | HRH3SIGMAR1 | |
| SCHEMBL17526234 | 0.78 | HRH3 (0.55) | HRH3SIGMAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090226411-A1 | CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS | AVENTIS PHARMA S.A. (FR) | 2009-09-10 | — | — | US | disclosed |
| US-20090226411-A1 | CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS | AVENTIS PHARMA S.A. (FR) | 2009-09-10 | — | — | US | disclosed |
| US-7482352-B2 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2009-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226411-A1 | CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS | DPYD, NTPCR, NME1 | HRH3 4106/4885SIGMAR1 2658/4885MAPT 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.